Citations

Clear

44 citation(s) found for "Horowitz, Mary".

High-Dose Chemotherapy and Autologous Stem-Cell Transplantation for Ovarian Cancer: An Autologous Blood and Marrow Transplant Registry Report
Stiff, Patrick J., Veum-Stone, Judith, Lazarus, Hillard M., Ayash, Lois, Edwards, John R., Keating, Armand, Klein, John P., Oblon, David J., Shea, Thomas C., Thomé, Stephan, Horowitz, Mary M., Stiff, Patrick J., Veum-Stone, Judith, Lazarus, Hillard M., Ayash, Lois, Edwards, John R., Keating, Armand, Klein, John P., Oblon, David J., Shea, Thomas C., Thomé, Stephan, Horowitz, Mary M.

Mayo Clinic

Annals of Internal Medicine | April 12, 2013 | Volume: 133 | Issue: 7 | Pages: 504-515

10.7326/0003-4819-133-7-200010030-00009 | PMID 11015163 Get It

Risk factors for acute GVHD and survival after hematopoietic cell transplantation
Jagasia, Madan , Arora, Mukta , Urbano-Ispizúa, Álvaro , Pavletic, Steven Z. , Haagenson, Michael , Zhang, Mei-Jie , Antin, Joseph H. , Bolwell, Brian J., Bredeson, Christopher , Cahn, Jean‐Yves, Cairo, Mitchell S. , Gupta, Vikas , Lee, Stephanie J. , Litzow, Mark R. , Weisdorf, Daniel J. , Horowitz, Mary M. , Hahn, Theresa , Flowers, Mary E.D. , Chao, Nelson J. , McCarthy, Philip L. , Cutler, Corey S. , Gale, Robert Peter , Weisdorf, Dan , Gupta, Vikas , Lee, Stephanie J

Mayo Clinic

Blood | October 19, 2011 | Volume: 119 | Issue: 1 | Pages: 296-307

10.1182/blood-2011-06-364265 | PMID 22010102 Get It

Abstract Risk factors for acute GVHD (AGVHD), overall survival, and transplant-related mortality were evaluated in adults receiving allogeneic hematopoietic cell transplants (1999-2005) from HLA-identical sibling donors (SDs; n = 3191) or unrelated donors (URDs; n = 2370) and reported to the Center for International Blood and Marrow Transplant Research, Minneapolis, MN. To understand the impact of transplant regimen on AGVHD risk, 6 treatment categories were evaluated: (1) myeloablative conditioning (MA) with total body irradiation (TBI) + PBSCs, (2) MA + TBI + BM, (3) MA + nonTBI + PBSCs, (4) MA + nonTBI + BM, (5) reduced intensity conditioning (RIC) + PBSCs, and (6) RIC + BM. The cumulative incidences of grades B-D AGVHD were 39% (95% confidence interval [CI], 37%-41%) in the SD cohort and 59% (95% CI, 57%-61%) in the URD cohort. Patients receiving SD transplants with MA + nonTBI + BM and RIC + PBSCs had significantly lower risks of grades B-D AGVHD than patients in other treatment categories. Those receiving URD transplants with MA + TBI + BM, MA + nonTBI + BM, RIC + BM, or RIC + PBSCs had lower risks of grades B-D AGVHD than those in other treatment categories. The 5-year probabilities of survival were 46% (95% CI, 44%-49%) with SD transplants and 33% (95% CI, 31%-35%) with URD transplants. Conditioning intensity, TBI and graft source have a combined effect on risk of AGVHD that must be considered in deciding on a treatment strategy for individual patients.
The graft-versus-leukemia effect using matched unrelated donors is not superior to HLA-identical siblings for hematopoietic stem cell transplantation
Ringdén, Olle , Pavletic, Steven Z. , Anasetti, Claudio , Wang, Tao , Antin, Joseph H. , Bartolomeo, Paolo Di , Bolwell, Brian J., Bredeson, Christopher , Cairo, Mitchell S. , Gupta, Vikas , Hahn, Theresa , Hale, Gregory A., Halter, Jörg , Jagasia, Madan , Litzow, Mark R. , Marks, David I. , Cowan, Morton J. , Petersdorf, Effie W. , Russell, James A. , Schiller, Gary J. , Schouten, Harry C. , Verdonck, Leo F. , Horowitz, Mary M. , Arora, Mukta , Barrett, A. John , Wang, Dan , Gale, Robert Peter , Locatelli, Franco , McCarthy, Philip L. , Spellman, Stephen R. , Wingard, John R. , Halter, Joerg , Ringden, Olov , Gupta, Vikas

Mayo Clinic

Blood | December 5, 2008 | Volume: 113 | Issue: 13 | Pages: 3110-3118

10.1182/blood-2008-07-163212 | PMID 19059878 Get It

AbstractDo some patients benefit from an unrelated donor (URD) transplant because of a stronger graft-versus-leukemia (GVL) effect? We analyzed 4099 patients with acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), and chronic myeloid leukemia (CML) undergoing a myeloablative allogeneic hematopoietic cell transplantation (HCT) from an URD (8/8 human leukocyte antigen [HLA]–matched, n = 941) or HLA-identical sibling donor (n = 3158) between 1995 and 2004 reported to the CIBMTR. In the Cox regression model, acute and chronic GVHD were added as time-dependent variables. In multivariate analysis, URD transplant recipients had a higher risk for transplantation-related mortality (TRM; relative risk [RR], 2.76; P < .001) and relapse (RR, 1.50; P < .002) in patients with AML, but not ALL or CML. Chronic GVHD was associated with a lower relapse risk in all diagnoses. Leukemia-free survival (LFS) was decreased in patients with AML without acute GVHD receiving a URD transplant (RR, 2.02; P < .001) but was comparable to those receiving HLA-identical sibling transplants in patients with ALL and CML. In patients without GVHD, multivariate analysis showed similar risk of relapse but decreased LFS for URD transplants for all 3 diagnoses. In conclusion, risk of relapse was the same (ALL, CML) or worse (AML) in URD transplant recipients compared with HLA-identical sibling transplant recipients, suggesting a similar GVL effect.
Impact of prior imatinib mesylate on the outcome of hematopoietic cell transplantation for chronic myeloid leukemia
Lee, Stephanie J. , Kukreja, Manisha, Szer, Jeff , Arora, Mukta , Woolfrey, Ann E. , Cervantes, Francisco , Halter, Joerg , Marks, David I. , Olavarría, Eduardo, Stadtmauer, Edward A. , Abecasis, Manuel, Gupta, Vikas , Khoury, H. Jean, Hale, Gregory A., Rizzieri, David A. , Antin, Joseph H. , Bolwell, Brian J., Carabasi, Matthew, Copelan, Edward A. , İlhan, Osman , Litzow, Mark R. , Schouten, H, Zander, Axel R., Horowitz, Mary M. , Halter, Jörg , Wang, Tao , Giralt, Sergio , Champlin, Richard E. , Gale, Robert Peter , Keating, Armand , McCarthy, Philip L. , George, Biju , Liesveld, Jane L. , Maziarz, Richard Thomas , Gupta, Vikas , Lee, Stephanie J

Mayo Clinic

Blood | July 30, 2008 | Volume: 112 | Issue: 8 | Pages: 3500-3507

10.1182/blood-2008-02-141689 | PMID 18664621 Get It

AbstractImatinib mesylate (IM, Gleevec) has largely supplanted allogeneic hematopoietic cell transplantation (HCT) as first line therapy for chronic myeloid leukemia (CML). Nevertheless, many people with CML eventually undergo HCT, raising the question of whether prior IM therapy impacts HCT success. Data from the Center for International Blood and Marrow Transplant Research on 409 subjects treated with IM before HCT (IM+) and 900 subjects who did not receive IM before HCT (IM−) were analyzed. Among patients in first chronic phase, IM therapy before HCT was associated with better survival but no statistically significant differences in treatment-related mortality, relapse, and leukemia-free survival. Better HLA-matched donors, use of bone marrow, and transplantation within one year of diagnosis were also associated with better survival. A matched-pairs analysis was performed and confirmed a higher survival rate among first chronic phase patients receiving IM. Among patients transplanted with advanced CML, use of IM before HCT was not associated with treatment-related mortality, relapse, leukemia-free survival, or survival. Acute graft-versus-host disease rates were similar between IM+ and IM− groups regardless of leukemia phase. These results should be reassuring to patients receiving IM before HCT.